- 本次重大合并将加速提升公司在全球医疗健康领域的影响力，在癌症诊疗全流程，成为客户和患者强大的合作伙伴，同时助力应对许多最具威胁的疾病
- 瓦里安成为西门子医疗旗下的新业务部门，也标志着西门子医疗在实施公司“2025战略”的过程中迈出了重要步伐
- 预计从2025财年开始，每年至少可实现3亿欧元的协同效益
2021年4月15日，德国，埃尔朗根——西门子医疗（法兰克福证交所代码：SHL）今天宣布，已顺利完成对瓦里安医疗系统公司的收购。收购交易此前于2020年8月2日披露。
西门子医疗监事会主席Ralf P. Thomas教授表示：“瓦里安加入之后，西门子医疗将拥有医疗科技领域最全面的产品组合，有望给公司带来巨大的价值创造潜力。凭借高度一体化的经营策略，西门子医疗将把全球抗癌事业提升到全新的高度。”
西门子医疗首席执行官孟天齐（Bernd Montag）博士表示：“随着交易的完成，我们现在已做好准备，一步实现两次飞跃：一方面推动公司抗癌业务的飞跃；另一方面提升公司在医疗健康行业的整体影响力。我们将共同成为一个强大且值得信赖的合作伙伴，能够在癌症诊疗全流程以及所有主要的临床路径上，为客户和患者提供支持。”
西门子医疗旗下瓦里安首席执行官陶克瑞（Chris Toth）指出：“瓦里安和西门子医疗此次合并具有重大意义，合并后的公司将满足日益增长的个性化、数据化诊断和精准癌症治疗的需求，有效应对全球日益增长的癌症发病率。我们将整合双方独具优势又高度互补的产品组合和能力，支持肿瘤临床医生和患者取得更好的疗效，从而持续迈向我们的愿景——创造一个无惧癌症的世界。”
合并后的公司将打造独一无二又高度融合的医学影像、实验室诊断、人工智能和治疗产品组合，在助力全球抗癌事业的同时，实现巨大的价值创造潜力。此次收购与西门子医疗的“升级（Upgrading）”战略阶段完美契合。随着今天收购的完成，瓦里安预计将在前12个月内为西门子医疗的每股收益做出积极贡献。西门子医疗的目标是从2025财年开始，每年至少实现3亿欧元的协同效益。
瓦里安和西门子医疗将基于此前“EnVision”项目框架下所建立的长期战略合作伙伴关系，全面构建包括治疗管理在内的数字化、诊断和治疗生态系统。随着瓦里安的加入，西门子医疗将利用人工智能辅助分析技术，深入开发和提供基于数据的精准医疗服务，重新定义癌症诊断、治疗服务和愈后管理。通过开展癌症早期准确发现与高效诊断，提高治疗质量并扩大服务范围，西门子医疗将助力瓦里安加快实现使命——减少癌症患者所面临的不确定性，提高癌症患者生存率。
西门子医疗在2019财年末完成公司“2025战略”的第一阶段。在此期间，公司成功实施首次公开募股（IPO），并推出了AI-Rad Companions等重大创新产品。随着2020财年的开始，西门子医疗进入“2025战略 ”的第二阶段。完成“升级 ”阶段后，西门子医疗的盈利性增长将更上一层楼。此前通过收购Corindus和ECG管理咨询公司，公司已经加强了在相邻增长市场的产品和服务。收购瓦里安后，西门子医疗已经做好了扩大现有市场、进入邻近市场和开拓全新市场的准备。
瓦里安的普通股在纽约证券交易所今天开盘前停止交易。
该新闻稿发布在 https://www.healthcare.siemens.com.cn/Upgrading，更多信息，请访问 https://www.corporate.siemens-healthineers.com/press/features/varian。
媒体垂询
西门子医疗 苏洁
电子邮箱：su.js.jie@siemens-healthineers.com
Siemens Healthineers AG (listed in Frankfurt, Germany: SHL) is shaping the future of healthcare. As a leading medical technology company headquartered in Erlangen, Germany, Siemens Healthineers enables healthcare providers worldwide through its regional companies to increase value by empowering them on their journey towards expanding precision medicine, transforming care delivery, improving the patient experience, and digitalizing healthcare. Siemens Healthineers is continuously developing its product and service portfolio, with AI-supported applications and digital offerings that play an increasingly important role in the next generation of medical technology. These new applications will enhance the company's foundation in in-vitro diagnostics, image-guided therapy, in-vivo diagnostics, and innovative cancer care. Siemens Healthineers also provides a range of services and solutions to enhance healthcare providers' ability to provide high-quality, efficient care to patients. In fiscal 2020, which ended on September 30, 2020, Siemens Healthineers generated revenue of €14.5 billion and adjusted EBIT of €2.2 billion. Following the acquisition of Varian Medical Systems, Inc. the company has approximately 65,000 employees worldwide. Further information is available at www.siemens-healthineers.com.
DISCLAIMER
This announcement is not directed to, or intended for distribution to or use by, any natural person or entity that is a citizen or resident or located in any locality, state, country or other jurisdiction where such distribution, publication, availability or use would be contrary to law or regulation of such jurisdiction or which would require any registration or licensing within such jurisdiction. Any failure to comply with these restrictions may constitute a violation of the laws of other jurisdictions.
The Company's securities have not been and will not be registered under the United States Securities Act of 1933, as amended (the "Securities Act"), and may not be offered or sold in the United States absent registration or an exemption from registration under the Securities Act.
This announcement includes "forward-looking statements". These statements contain the words "anticipate", "believe", "intend", "estimate", "plan", "expect", "target" and "will" and words of similar meaning. All statements other than statements of historical facts included in this announcement, including, without limitation, those regarding Siemens Healthineers' financial position, business strategy, the expected financial impact of the acquisition of Varian (including costs and revenue synergies), plans and objectives of management for future operations (including the achievement of costs and revenue synergies) are forward-looking statements. By their nature, such forward-looking statements involve known and unknown risks, uncertainties and other important factors that could cause the actual results, performance or achievements of the Siemens Healthineers to be materially different from results, performance or achievements expressed or implied by such forward-looking statements. Such forward-looking statements are based on numerous assumptions regarding Siemens Healthineers' present and future business strategies and the market environment in which Siemens Healthineers will operate in the future. Each of the companies referred to in this announcement, the relevant group entities and their respective affiliates, agents, directors, officers, employees and advisers, expressly disclaims any obligation or undertaking to update any forward-looking statements contained herein. All forward-looking statements only speak as of the date when they were made and Siemens Healthineers neither intends, nor assumes any obligation, unless required by law, to update or revise these forward-looking statements in light of developments which differ from those anticipated. You are urged to consider these factors carefully in evaluating the forward-looking statements in this announcement and not to place undue reliance on such statements.
This document includes – in the applicable financial reporting framework not clearly defined – supplemental financial measures (financial key performance indicators) that are or may be alternative performance measures (non-GAAP-measures). These supplemental financial measures may have limitations as analytical tools and should not be viewed in isolation or as alternatives to measures of Siemens Healthineers' net assets and financial positions or results of operations as presented in accordance with the applicable financial reporting framework in its half-year consolidated financial statements and consolidated financial statements. Other companies that report or describe similarly titled alternative performance measures may calculate them differently, which may therefore not be comparable.
Due to rounding, numbers presented throughout this and other documents may not add up precisely to the totals provided and percentages may not precisely reflect the absolute figures to which they refer.
This document is an English language translation of the German document. In case of discrepancies, the German language document is the sole authoritative and universally valid version.
The information contained in this document is provided as of the date of its publication and is subject to change without notice.
Please find further explanations to our financial key performance indicators in chapter "A.2 Financial performance system" and in the notes to the consolidated financial statements note 29 "Segment information" in the Annual Report 2020 of Siemens Healthineers. Additional information on reconciliations is also included in the Analyst Presentation. These documents are available under the following internet link https://www.corporate.siemens-healthineers.com/investor-relations/presentations-financial-publications.